Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin.

Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG.

J Gastroenterol. 2013 Dec;48(12):1401-10. doi: 10.1007/s00535-013-0761-x. Epub 2013 Mar 6.

PMID:
23463400
2.

Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.

Fernández I, Loinaz C, Hernández O, Abradelo M, Manrique A, Calvo J, Manzano M, García A, Cambra F, Castellano G, Jiménez C.

Transpl Infect Dis. 2015 Oct;17(5):695-701. doi: 10.1111/tid.12434. Epub 2015 Oct 3.

PMID:
26257166
3.

Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.

Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK, Choi JY.

J Gastroenterol Hepatol. 2014 Jan;29(1):151-6. doi: 10.1111/jgh.12403.

PMID:
24117684
4.

Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.

Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E.

Transpl Infect Dis. 2012 Oct;14(5):479-87. doi: 10.1111/j.1399-3062.2012.00741.x. Epub 2012 May 25.

PMID:
22624695
5.

Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.

Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mössner J, Berg T, Tillmann HL, Wiegand J.

Transpl Infect Dis. 2011 Jun;13(3):299-302. doi: 10.1111/j.1399-3062.2010.00591.x. Epub 2010 Dec 16.

PMID:
21159112
6.

Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.

Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL.

Transplantation. 2014 Apr 27;97 Suppl 8:S53-9. doi: 10.1097/01.tp.0000446278.43804.f9.

PMID:
24849836
7.

Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?

Choudhary NS, Saraf N, Saigal S, Mohanka R, Rastogi A, Goja S, Menon PB, Soin AS.

Transpl Infect Dis. 2015 Jun;17(3):329-33. doi: 10.1111/tid.12369. Epub 2015 May 26.

PMID:
25682715
8.

Antiviral treatment for hepatitis B virus recurrence following liver transplantation.

Lee S, Kwon CH, Moon HH, Kim TS, Roh Y, Song S, Shin M, Kim JM, Park JB, Kim SJ, Joh JW, Lee SK.

Clin Transplant. 2013 Sep-Oct;27(5):E597-604. doi: 10.1111/ctr.12212.

PMID:
24093615
9.

Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.

Gao YJ, Zhang M, Jin B, Meng FP, Ma XM, Liu ZW, Su HB, Zhao JM, Li HW.

J Gastroenterol Hepatol. 2014 Mar;29(3):554-60. doi: 10.1111/jgh.12404.

PMID:
24117714
10.

Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.

Singer GA, Zielsdorf S, Fleetwood VA, Alvey N, Cohen E, Eswaran S, Shah N, Chan EY, Hertl M, Fayek SA.

Transplant Proc. 2015 Mar;47(2):478-84. doi: 10.1016/j.transproceed.2014.11.029.

PMID:
25769595
11.

New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.

Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E.

Transpl Int. 2014 Oct;27(10):1022-8. doi: 10.1111/tri.12370. Epub 2014 Jun 30.

12.
13.

High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.

Cholongitas E, Papatheodoridis GV.

Am J Transplant. 2013 Feb;13(2):353-62. doi: 10.1111/j.1600-6143.2012.04315.x. Epub 2012 Nov 8. Review.

14.

The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.

Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB.

Clin Transplant. 2012 Sep-Oct;26(5):E561-9. doi: 10.1111/ctr.12022.

PMID:
23061767
16.

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.

Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW; Australasian Liver Transplant Study Group.

Gastroenterology. 2007 Mar;132(3):931-7. Epub 2007 Jan 5.

PMID:
17383422
17.

A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.

Chen G, Liu H, Hu ZQ, Bai JH, Liu QY, Zhao YP, Gan XM, Wang F, Wang DD, Ma LJ, Li L.

Eur J Gastroenterol Hepatol. 2015 Aug;27(8):901-6. doi: 10.1097/MEG.0000000000000388.

PMID:
26011237
18.

Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.

Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B.

J Clin Virol. 2013 Sep;58(1):67-73. doi: 10.1016/j.jcv.2013.06.035. Epub 2013 Jul 20.

19.

Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.

Wang X, Zhang C, Zhu Y, Xiong Y, Wang Y.

Antiviral Res. 2014 Mar;103:71-7. doi: 10.1016/j.antiviral.2014.01.009. Epub 2014 Jan 23.

PMID:
24462954
20.

Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.

Viganò M, Bhoori S, Lampertico P, Donato MF, Iavarone M, Grossi G, Facciorusso A, Caccamo L, Rossi G, Colombo M, Mazzaferro V.

Liver Int. 2015 Sep;35(9):2187-93. doi: 10.1111/liv.12835. Epub 2015 Apr 21.

PMID:
25809541

Supplemental Content

Support Center